Drug Profile
Fluticasone propionate/glycopyrronium bromide/salmeterol xinafoate
Alternative Names: PSX 3001Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Prosonix
- Developer NIOX
- Class Anti-inflammatories; Antiasthmatics; Antibronchitics; Antispasmodics; Bronchodilators; Glucocorticoids; Phenethylamines; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in Unknown (Intranasal, Aerosol)